WuXi AppTec
药明康德
WuXi AppTec is a contract research organization (CRO) that serves as an outsourced R&D partner for pharmaceutical companies, handling drug discovery research by employing chemistry and biology specialists . It has been described as occupying a role analogous to Foxconn in consumer electronics—an essential but labor-intensive, lower-margin link in the global pharmaceutical value chain . The company went public on the Shanghai Stock Exchange in May 2018 and was at that time the largest CRO globally . Its business model centers on leveraging China's large pool of relatively low-cost, highly educated knowledge workers . In its organizational history, Zhigang Chen served as its first Chief Digital Officer .
AI-generated — may contain errors, please verify.
Coverage
Silicon Valley's Booming Longevity Economy, Its Commercial Path Is Right in Front of Us
"The first people who will live to 1,000 may already be alive today."
峰瑞资本·The "OpenAI Moment" for Pharma Labs: HeTan AI Raises 50 Million Yuan, Robot Scientists Step Onto the Lab Bench
The story of robot scientists has only just begun.
云启资本·HETAN Intelligence Closes 50 Million Yuan Funding Round, as Robots Make Real Inroads into Labs
Veteran founders with backgrounds at Alibaba, Tencent, and WuXi AppTec.
暗涌Waves·Entrepreneurship Is the Most Hardcore Way for Young People to Change the World | Mono X Campus
Be a long-term partner to founders, not a short-term "referee."
Monolith砺思资本·Deep Dive: China's "DeepSeek Moment" in Biotech | FreeS Fund Report
A Watershed Year for China's Innovative Drug Industry
峰瑞资本·Ban one TikTok, and a thousand TikToks will rise in its place | Undercurrent Worldview
The Perils of Globalization for Chinese Companies
暗涌Waves·Yunqi Capital Attent!on Podcast | Founders Up and Down the Supply Chain: From Embodiment to Intelligence, How Is AI "Awakening" Robots?
Let's Talk About the Messy Reality of Deployment and Application Bottlenecks
云启资本·Embodied Intelligence + Drug Discovery = ? C12.ai Unveils Industry's First Pharmaceutical R&D Intelligent Robot | Yunqi Capital
Accelerating Drug Discovery and Development
云启资本·Vol.05 Has AI "Woken Up" the Robots? A Look at the Many Applications and Bottlenecks of Embodied Intelligence
云启资本·One Step Ahead: Unlocking the N Possibilities of Embodied Intelligence | Yunqi Gathering · Yunqi Capital Demo Day Now Open for Registration
When Embodied Intelligence Comes Knocking
云启资本·What Are the Opportunities for Biotech Over the Next Decade? | A FreeS Fund Conversation
Breaking Through the "Great Stagnation" in Technology: Biotechnology Is a Critical Breakthrough
峰瑞资本·"There Will Come a Moment When Technology Defeats Human Experience" | A Conversation with FreeS Fund
"There will come a moment when technology surpasses human experience."
峰瑞资本·Yinjia Biotech Closes Pre-A Round, Advancing Its High-End Protein Platform to New Heights
Build a leading domestic "protein artisan" platform.
高榕创投·Are Returnee Entrepreneurs Losing Their Edge? | 2021 FreeS Fund China-US Venture Forum Transcript
Launch a Startup or Take the "Soft Landing" Through Employment?
峰瑞资本·Blue Ocean Strategy: How Early-Stage Biopharma Startups Can Break Through and Win with Big Pharma | FreeS Fund 2020 Biopharma Summit Session 3 — Registration Open
From "Me Worse" to "First in Class": How Can Biopharma Companies Compete Through Differentiation?
峰瑞资本·In Our Sixth Year, FreeS Fund Is Hiring Investors | Let's Do What's Right, Not What's Easy
Betting on the power of innovation, staying research-driven.
峰瑞资本·Investment Opportunities in the Pharmaceutical and Chemical Industry Upgrade | Frees Fund
Technology Transfer and Innovation-Driven Growth
峰瑞资本·2018 was a tough year, but absolutely one with inflection-point significance.
You don't need to get clever or cut corners. Just do what aligns with the cycle and the structure, and you'll make money in this cycle.
峰瑞资本·Li Feng Column | The Trade War Gets a Comma, but China's Secret Weapon Is Just About to Show Its Edge
What makes China's economic experience distinctive is that much of it consists of "the unintended consequences of human action."
峰瑞资本·
